Virtual symposium “Hot topics and challenges in SBRT for oligometastatic disease”

EORTC is pleased to invite you to a virtual symposium organized by the EORTC & ESTRO OligoCare project. Esteemed speakers will discuss the latest evidence and clinical trials in the field of oligometastatic disease, sharing the latest insights gained from the OligoCare cohort.

Additionally, we will discuss the TwiCs methodology’s application in radiation oncology, specifically addressing the “optimal” fractionation for SABR in patients with oligometastases. We will explore the scientific and operational aspects of the upcoming TwiCs research question: “OligoCare TwiCs comparing acute toxicity in single-fraction vs multiple-fraction SBRT for metastasis-directed treatment.”

Join us on:
30 January 2024
From 16:00 to 18:00 CET

Speakers:

Daniela Greto
Giulio Francolini
Chiaojung Jillian Tsai
David Palma
Shankar Siva
Piet Ost
Matthias Guckenberger
Sarah Nuyens

Agenda

EORTC and ESTRO Collaboration

E²RADIatE is a joined collaboration of two international not-for-profit organisations:

The European Organisation for Research and Treatment of Cancer (EORTC) is Europe’s leading multidisciplinary clinical cancer research organisation, which unites research experts worldwide to define better treatments for cancer patients and improve their survival and quality of life.

The European Society for Radiotherapy and Oncology (ESTRO) is a scientific non-profit organisation whose ambition is to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it.

The SPRINT TwiCs is in the OligoCare cohort of E²-RADIatE, which is generously supported by Walgreens Boots Alliance.